Intravesical Gentamicin for Recurrent Urinary Tract Infections: On a Roll After 39 Years
A recent article in Neurourology and Urodynamics asked an important and timely question: Is intravesical gentamicin the new gold standard for managing refractory recurrent urinary tract infections? The answer, at least for now, is best framed with some caution.
Intravesical gentamicin is not yet a universal standard for all patients with refractory recurrent urinary tract infections (rUTI). However, for carefully selected patients — particularly those already performing intermittent catheterization, those with complex lower urinary tract dysfunction, or those with recurrent infections involving resistant organisms — the accumulated clinical experience and emerging literature make it an increasingly compelling strategy.
The interest in this approach is easy to understand. Recurrent UTIs are common, costly, and often frustrating for both patients and clinicians. They contribute substantially to antibiotic exposure, and in an era of increasing antimicrobial resistance, the need for effective alternatives to repeated oral antibiotics has become more urgent.
Why Refractory rUTI Remains a Clinical Problem
UTIs account for a large proportion of antibiotic prescriptions, and recurrent infections are associated with direct health care costs, impaired quality of life, and psychosocial burden. Approximately one in three women will experience a UTI during her lifetime, and a substantial proportion will have recurrence within months of the initial infection.
The problem is often more complicated in patients with reconstructed urinary tracts, neurogenic lower urinary tract dysfunction, catheterization dependence, bladder emptying problems, or a history of resistant organisms. In these settings, repeated courses of oral antibiotics may become less effective, less desirable, or both.
Mechanistically, recurrent infection may be facilitated by bacterial internalization into bladder epithelial cells, intracellular bacterial communities, impaired mucosal defenses, and alterations in the glycosaminoglycan layer. These factors help explain why rUTI can persist despite apparently appropriate antimicrobial therapy.
Non-antibiotic prevention strategies have been explored, including behavioral interventions, dietary supplementation, probiotics, D-mannose, methenamine hippurate, estrogens, vaccines, immunostimulants, and intravesical glycosaminoglycan therapies. Some of these approaches are promising, but higher-quality evidence is still needed before firm recommendations can be made broadly.
The Historical Basis for Intravesical Gentamicin
The concept of intravesical antibiotic administration is not new. In 1987, McGuire and Savastano reported successful treatment of women with intractable bacterial cystitis associated with residual urine volume and self-intermittent catheterization using gentamicin instilled directly into the bladder.
A later report from the University of Michigan further clarified the rationale: intravesical antibiotic therapy delivers the drug directly to the site of infection while minimizing systemic exposure. This bypasses the gastrointestinal tract and may reduce some of the complications associated with oral antimicrobial therapy. In that early work, detectable serum gentamicin levels were not observed in most patients, serum creatinine remained unchanged, and adverse events were minimal.
These observations established the foundational appeal of the approach: high local antibiotic concentration, limited systemic absorption, and potential reduction in oral antibiotic exposure.
Clinical Experience in Neurogenic and Complex Bladder Populations
Despite the rationale, widespread adoption did not occur initially. Use remained largely confined to specialized centers, particularly among patients already performing catheterization.
Subsequent pediatric and adult series continued to support the safety and potential effectiveness of intravesical gentamicin in complex urologic populations. Reports from Cincinnati Children’s Hospital, Bristol Urological Institute, and the University of Michigan described reductions in symptomatic UTIs, oral antibiotic use, and breakthrough infections in selected cohorts. Importantly, these studies generally found minimal systemic absorption and few treatment-related adverse events.
The University of Michigan experience is particularly relevant. In neurogenic bladder patients performing intermittent catheterization, prophylactic intravesical gentamicin was associated with fewer symptomatic UTIs, fewer courses of oral antibiotics, and no apparent increase in antimicrobial resistance. Later patient-reported outcomes also suggested high satisfaction among those who continued therapy.
A systematic review in patients with neurogenic lower urinary tract dysfunction similarly found reduced UTI frequency, decreased oral antibiotic use, and lower prevalence of multidrug-resistant bacteria. Across studies, serious adverse events attributable to intravesical gentamicin were uncommon.
What Recent Evidence Adds
The recent Chitteti et al. study brings this discussion into the current clinical environment. In a single-center prospective study of patients with complex rUTI treated with intravesical gentamicin over a 24-month period, patients self-administered instillations on a structured treatment schedule after being taught intermittent self-catheterization.
The findings were encouraging. Overall UTI frequency decreased in most patients, hospitalization rates for urosepsis declined, multidrug resistance patterns improved, and patient-reported outcomes were favorable. Treatment success was reported in the majority of patients.
These results are important, but they must be interpreted in context. The study was not randomized, the patient population was heterogeneous, and the findings remain most applicable to selected patients with refractory or complex rUTI rather than to all patients with uncomplicated recurrent infection.
Other Intravesical Therapies
Intravesical gentamicin is not the only bladder-directed strategy under investigation. Other agents, including hyaluronic acid, chondroitin sulfate, povidone iodine, heparin, and fosfomycin, have also been studied.
A recent systematic review and meta-analysis found that intravesical aminoglycosides, particularly gentamicin, were associated with reductions in UTI recurrence. Hyaluronic acid monotherapy also showed promise, likely through restoration of the bladder’s glycosaminoglycan layer. However, the literature remains limited by small study size, observational designs, variable dosing regimens, heterogeneous patient populations, and inconsistent outcome definitions.
In short, the broader intravesical therapy field is promising, but not yet definitive.
Guideline Positioning and Practical Considerations
Intravesical gentamicin is not currently emphasized in major AUA or EAU guideline recommendations for recurrent UTI. When intravesical glycosaminoglycan therapies are discussed, the evidence is generally characterized as limited or promising rather than conclusive.
This is an important practical point. Intravesical gentamicin remains an off-label approach, and its use requires patient counseling, shared decision-making, and attention to patient selection. It is most compelling in patients who have exhausted standard options, have repeated antibiotic exposure, have resistant organisms, or are already performing intermittent catheterization.
The ongoing VESPER trial should help clarify the comparative role of intravesical gentamicin, glycosaminoglycan replacement therapy, and low-dose antibiotic prophylaxis in women with recurrent UTI. Its results may provide stronger evidence to guide future practice.
Bottom Line
So, is intravesical gentamicin the new gold standard for refractory rUTI?
At this point, the most defensible answer is: not universally — but possibly for carefully selected patients.
The evidence is strongest in complex populations, particularly those with neurogenic lower urinary tract dysfunction, catheterization dependence, resistant organisms, or repeated failure of conventional management. The safety data are reassuring, the antimicrobial stewardship rationale is persuasive, and the clinical outcomes reported to date are encouraging.
However, broader adoption will require more rigorous prospective and comparative data. Until then, intravesical gentamicin should be viewed not merely as an investigational curiosity, but as a potentially valuable option in the management of difficult recurrent UTI when used thoughtfully, selectively, and with appropriate patient counseling.
Written by: Alan Wein, MD, PhD, FACS, Professor of Clinical Urology, Department of Urology, Desai Sethi Urology Institute (DSUI), University of Miami Miller School of Medicine, University of Miami Health Systems, Miami, FL